

---

## Press Release

Stockholm, Sweden, November 30, 2021

### Immunicum and PCI Biotech Announce an Extension to Their Research Collaboration to Explore Novel Cancer Vaccination Treatments

Immunicum AB (publ; IMMU.ST), a biopharmaceutical company focused on hard-to-treat established tumors and the prevention of cancer recurrence, and PCI Biotech Holding ASA (OSE: PCIB), a cancer focused biopharmaceutical company with a unique intracellular delivery technology via Photochemical Internalisation, announced today an extension of their current collaboration.

The companies jointly research the possibility to overcome current hurdles in cancer immunotherapy by introducing tumor independent immune targets into the tumor microenvironment, in combination with vaccination or adoptive immunotherapies. The so-called Tumor Independent Antigen concept, which has been invented by Immunicum, could benefit from PCI Biotech's antigen delivery technologies based on Photochemical Internalisation. Following the encouraging results of the first set of *in vitro* experiments, during which the delivery protocol of the combination treatment has been optimized, the companies have decided to move ahead to evaluate the novel therapeutic concept in animal models. While the first experiments were conducted by Immunicum, this further *in vivo* evaluation will be carried out by PCI Biotech.

Commenting on the announcement PCI Biotech's CEO, Per Walday said: *"The results of the initial collaborative experiments are encouraging, supporting the immune response enhancing capability of the fimaVACC platform technology. We are committed to this collaboration and are looking forward to the next series of experiments in animal models, which are aimed to generate data that could pave the way to a potential joint development program."*

Erik Manting, CEO of Immunicum added: *"At Immunicum, we are continuously studying novel immunotherapy concepts aimed to address hard-to-treat established tumors and to overcome the limitations of currently available cancer therapies. In this collaboration, we are combining our know-how and technology basis with that of PCI Biotech to design potential novel therapeutic concepts and we look forward to advancing the collaboration through *in vivo* studies as an important next step."*

#### **FOR MORE INFORMATION, PLEASE CONTACT:**

Erik Manting  
Chief Executive Officer  
E-mail: [ir@immunicum.com](mailto:ir@immunicum.com)

#### **INVESTOR RELATIONS**

Brendan Payne  
Stern Investor Relations  
Telephone: +1 212-698-8695  
E-mail: [brendan.payne@sternir.com](mailto:brendan.payne@sternir.com)

For Sweden:

Kristina Windrup Olander  
Spikinc AB  
Telephone: +46 8 732 8400  
E-mail: [ir@immunicum.com](mailto:ir@immunicum.com)

---

**MEDIA RELATIONS**

Eva Mulder and Sophia Hergenhan  
Trophic Communications  
Telephone: +49 89 2388 7731  
E-mail: [immu@trophic.eu](mailto:immu@trophic.eu)

**ABOUT IMMUNICUM AB (PUBL)**

Immunicum is a biopharmaceutical company focused on hard-to-treat established tumors and the prevention of cancer recurrence, two key challenges in oncology. We are leveraging our unparalleled expertise in allogeneic dendritic cell biology to develop an advanced clinical pipeline of novel, off-the-shelf, cell-based therapies for solid and blood-borne tumors. Based in Sweden and the Netherlands, Immunicum is publicly traded on the Nasdaq Stockholm. [www.immunicum.com](http://www.immunicum.com)

**ABOUT PCI BIOTECH**

PCI Biotech is a biopharmaceutical late-stage clinical development company focusing on development and commercialisation of novel therapies for the treatment of cancer through its innovative photochemical internalisation (PCI) technology platform. PCI is applied to three distinct anticancer paradigms: fimaCHEM (targeted enhancement of the first-line chemotherapeutic for treatment of bile duct cancer), fimaVACC (therapeutic vaccination and immunotherapy), and fimaNAC (intracellular delivery of nucleic acid therapeutics). [www.pcibiotech.com](http://www.pcibiotech.com)